Experiment Score: 83 | Rank: 94 | Category: Basic Mechanism | Disease: MS/Neurodegeneration
Is Epstein-Barr virus (EBV) a causal driver of multiple sclerosis (MS) requiring additional co-factors, or merely a necessary but insufficient co-factor that requires other triggers for disease manifestation? This distinction fundamentally shapes prevention strategies, therapeutic targets, and prognostic understanding.
This experiment addresses the fundamental unresolved question in MS etiology: while 99% of MS patients are EBV-seropositive vs 94% of age-matched controls (odds ratio ~6), and longitudinal studies show EBV infection precedes MS onset by years, the causal mechanism remains unknown[@handler2022]. The critical question is whether EBV actively drives MS pathology or merely establishes a permissive immunological environment. Despite EBV's near-universal presence in MS patients, MS prevalence is only 0.1-0.3% — indicating that EBV alone is far from sufficient.
¶ Phase 1: Longitudinal EBV Serostatus and MS Phenotype Mapping (Cohort: 200 MS patients, 100 EBV+ healthy controls)
- Baseline characterization: Comprehensive EBV serological profiling (VCA IgG, VCA IgM, EBNA IgG, EA IgG) + MS clinical phenotyping (RRMS, SPMS, PPMS, CIS)
- EBV epitope mapping: Mass spectrometry identification of EBV peptides generating cross-reactive T cell responses against myelin antigens (molecular mimicry screening)
- Longitudinal sampling: Annual CSF and blood collection over 5 years to track EBV reactivation markers (EBV DNA load, lytic vs latent gene expression) vs MS disease progression biomarkers (NfL, GFAP, OCB status)
- B cell clonality tracking: Use of B cell receptor repertoire sequencing to identify EBV-infected B cell clones expanding in MS vs controls
- iPSC-derived neuron/oligodendrocyte co-culture: Test whether EBV infection of B cells creates diffusible factors that damage neurons or oligodendrocyte precursor cells (OPCs)
- Humanized mouse model: EBV infection in HLA-DR2 transgenic mice with or without secondary hits (cuprizone demyelination, MOG immunization, vitamin D deficiency) to test combinatorial sufficiency
- Spatial transcriptomics of MS lesions: Map EBV RNA+ cells within active vs chronic inactive lesions — are EBV-infected B cells localized to sites of active demyelination or chronic inflammation?
- Genetic MR analysis: Use GWAS summary statistics for EBV seropositivity (n=8,000) and MS risk (n=50,000) to test whether genetic predisposition to EBV infection genetically causes MS
- Mediation analysis: Test whether EBV-associated genetic variants act through EBV infection status to confer MS risk, or through independent immunological pathways
| System |
Application |
Strength |
Limitation |
| Human cohort (200 pts) |
EBV serology + MS phenotype correlation |
Clinical relevance |
Cannot establish causality |
| iPSC neuron/B cell co-culture |
Test EBV diffusible factors for neurotoxicity |
Mechanistic |
No full immune system |
| HLA-DR2 humanized mouse |
EBV + environmental hits model |
In vivo + genetic |
EBV infection less robust in mice |
| Spatial transcriptomics (MS brain) |
EBV+ cell localization in lesions |
Direct human tissue |
Cross-sectional only |
| Mendelian randomization |
Causal inference from GWAS |
Genetic causal evidence |
Instrument strength dependent |
- Causal vs correlational determination: If MR shows genetic EBV susceptibility causally associates with MS risk, this supports causal model. If not, EBV is a necessary co-factor only.
- Secondary hit identification: Identification of 1-3 additional factors (genetic, environmental) that combine with EBV to produce MS
- Mechanistic pathway: Whether EBV drives MS through molecular mimicry, bystander activation, latent reservoir inflammation, or direct CNS infection
| Hypothesis |
Evidence That Would Support |
Expected Frequency |
| EBV is causal driver |
MR causal link + EBV+ cells in lesions + EBV factor neurotoxicity |
~30% of MS |
| EBV is necessary co-factor |
EBV required but insufficient + specific second hits needed |
~60% of MS |
| EBV is correlational |
No MR causal link + EBV+ cells absent from lesions |
~10% of MS |
- Technical feasibility: High — standard serology, sequencing, and iPSC methods are well-established
- Timeline: 36 months (18 mo cohort + 18 mo mechanistic studies)
- Cost estimate: $1.8M (cohort: $400K, iPSC: $500K, mouse studies: $600K, sequencing: $300K)
- Key dependencies: Access to MS brain tissue (Biobanks), well-characterized longitudinal MS cohort
- High relevance to narcolepsy (EBV + H1N1 flu vaccine trigger) — shared post-infectious autoimmunity model
- Relevant to Autoimmune Encephalitis — EBV-driven B cell dysregulation
- Relevant to ALS potential viral triggers (EBV shares with HHV-6)
- Applicable to understanding post-infectious neurodegeneration broadly
- Handler et al., EBV as the cause of multiple sclerosis: critical review (2022)
- Bjornevik et al., Longitudinal analysis of EBV prevalence and MS (2022)
- Pender et al., Defective T-cell control of EBV in MS (2017)
- Ricigliano et al., EBV antibodies and MS: longitudinal study (2022)
- Loquet et al., EBV-specific CD8+ T cell responses in MS (2024)
- Torke et al., Molecular mimicry between EBV and myelin (2020)
- Jagodic et al., B cell distribution and EBV latency in MS brain (2024)